O	0	4	High
O	4	5	-
O	5	15	throughput
O	16	32	pharmacogenetics
O	33	43	identifies
O	44	51	SLCO1A2
O	52	65	polymorphisms
O	66	68	as
O	69	79	candidates
O	80	82	to
O	83	92	elucidate
O	93	96	the
O	97	101	risk
O	102	104	of
O	105	112	febrile
O	113	124	neutropenia
O	125	127	in
O	128	131	the
O	132	138	breast
O	139	145	cancer
O	146	150	RAPP
O	150	151	-
O	151	153	01
O	154	159	trial
O	159	160	.

O	161	164	The
O	165	169	RAPP
O	169	170	-
O	170	172	01
O	173	181	clinical
O	182	187	trial
O	188	196	compared
O	197	200	two
O	201	209	adjuvant
O	210	224	chemotherapies
O	224	225	,
B-intervention	226	237	doxorubicin
I-intervention	238	242	plus
I-intervention	243	252	docetaxel
O	253	254	(
O	254	257	arm
O	258	259	A
O	259	260	)
O	261	267	versus
B-control	268	279	doxorubicin
I-control	280	284	plus
I-control	285	301	cyclophosphamide
O	302	303	(
O	303	306	arm
O	307	308	B
O	308	309	)
O	309	310	,
O	311	313	in
B-total-participants	314	317	627
B-eligibility	318	323	women
I-eligibility	324	328	with
I-eligibility	329	335	breast
I-eligibility	336	342	cancer
O	342	343	.

O	344	346	It
O	347	354	stopped
O	355	366	prematurely
O	367	371	when
O	372	377	three
O	378	384	severe
O	385	392	adverse
O	393	399	events
O	400	408	occurred
O	409	414	among
O	415	423	patients
O	424	428	with
O	429	436	febrile
O	437	448	neutropenia
O	449	450	(
O	450	452	FN
O	452	453	)
O	453	454	,
O	455	458	all
O	459	461	in
O	462	465	the
O	466	469	arm
O	470	471	A
O	471	472	.

B-outcome	473	475	FN
O	476	484	occurred
O	485	487	in
B-iv-bin-percent	488	490	40
I-iv-bin-percent	490	491	.
I-iv-bin-percent	491	492	8
I-iv-bin-percent	492	493	%
O	494	495	(
B-iv-bin-abs	495	498	126
O	498	499	/
B-intervention-participants	499	502	311
O	502	503	)
O	504	506	in
O	507	510	arm
O	511	512	A
O	513	519	versus
B-cv-bin-percent	520	521	7
I-cv-bin-percent	521	522	.
I-cv-bin-percent	522	523	1
I-cv-bin-percent	523	524	%
O	525	526	(
B-cv-bin-abs	526	528	22
O	528	529	/
B-control-participants	529	532	316
O	532	533	)
O	534	536	in
O	537	540	arm
O	541	542	B
O	542	543	.

O	544	546	We
O	547	559	investigated
O	560	566	Single
O	567	577	Nucleotide
O	578	591	Polymorphisms
O	592	593	(
O	593	597	SNPs
O	597	598	)
O	599	601	in
O	602	606	drug
O	607	618	transporter
O	619	622	and
O	623	633	metabolism
O	634	639	genes
O	640	651	potentially
O	652	664	incriminated
O	665	667	in
O	668	672	this
O	673	679	excess
O	680	682	of
O	683	685	FN
O	685	686	.

O	687	692	Using
O	693	694	a
O	695	704	dedicated
O	705	708	DNA
O	709	713	chip
O	713	714	,
O	715	717	we
O	718	724	tested
O	725	736	association
O	737	739	of
O	740	744	SNPs
O	745	754	belonging
O	755	757	to
O	758	760	97
O	761	772	transporter
O	773	776	and
O	777	779	68
O	780	792	metabolizing
O	793	798	genes
O	799	803	with
B-outcome	804	806	FN
O	807	817	occurrence
O	818	820	in
O	821	824	155
O	825	833	patients
O	834	842	enrolled
O	843	845	in
O	846	849	the
O	850	854	RAPP
O	854	855	-
O	855	857	01
O	858	863	trial
O	863	864	,
B-iv-bin-abs	865	867	85
O	868	870	in
O	871	874	arm
O	875	876	A
O	877	880	and
B-cv-bin-abs	881	883	70
O	884	886	in
O	887	890	arm
O	891	892	B
O	892	893	.

O	894	905	Association
O	906	911	study
O	912	914	in
O	915	918	the
O	919	921	85
O	922	930	patients
O	931	940	receiving
O	941	950	docetaxel
O	951	961	identified
O	962	965	two
O	966	970	SNPs
O	970	971	,
O	972	981	rs4762699
O	982	985	and
O	986	995	rs2857468
O	995	996	,
O	997	1001	both
O	1002	1009	located
O	1010	1012	in
O	1013	1016	the
O	1017	1024	SLCO1A2
O	1025	1029	gene
O	1029	1030	.

O	1031	1040	Haplotype
O	1041	1042	T
O	1042	1043	-
O	1043	1044	T
O	1045	1048	was
O	1049	1059	associated
O	1060	1064	with
O	1065	1066	a
O	1067	1071	high
B-outcome	1072	1076	risk
I-outcome	1077	1079	of
I-outcome	1080	1082	FN
O	1082	1083	:
B-iv-bin-percent	1084	1086	83
I-iv-bin-percent	1086	1087	.
I-iv-bin-percent	1087	1088	3
I-iv-bin-percent	1088	1089	%
O	1090	1092	of
O	1093	1101	patients
O	1102	1106	with
O	1107	1109	at
O	1110	1115	least
O	1116	1119	one
O	1120	1124	copy
O	1125	1127	of
O	1128	1129	T
O	1129	1130	-
O	1130	1131	T
O	1132	1138	versus
B-cv-bin-percent	1139	1141	32
I-cv-bin-percent	1141	1142	.
I-cv-bin-percent	1142	1143	8
I-cv-bin-percent	1143	1144	%
O	1145	1147	in
O	1148	1156	patients
O	1157	1161	with
O	1162	1167	other
O	1168	1178	haplotypes
O	1179	1180	(
O	1180	1184	odds
O	1185	1190	ratio
O	1191	1192	=
O	1193	1195	10
O	1195	1196	.
O	1196	1198	25
O	1198	1199	,
O	1200	1201	P
O	1202	1203	=
O	1204	1205	1
O	1205	1206	.
O	1206	1208	4e
O	1208	1209	-
O	1209	1210	4
O	1210	1211	)
O	1211	1212	.

O	1213	1215	In
O	1216	1217	a
O	1218	1230	multivariate
O	1231	1239	logistic
O	1240	1245	model
O	1246	1254	adjusted
O	1255	1258	for
O	1259	1268	treatment
O	1269	1272	arm
O	1272	1273	,
O	1274	1280	effect
O	1281	1283	of
O	1284	1293	haplotype
O	1294	1295	T
O	1295	1296	-
O	1296	1297	T
O	1298	1306	remained
O	1307	1318	significant
O	1319	1320	(
O	1320	1324	odds
O	1325	1330	ratio
O	1331	1332	=
O	1333	1334	6
O	1334	1335	.
O	1335	1337	84
O	1337	1338	,
O	1339	1340	P
O	1341	1342	=
O	1343	1344	1
O	1344	1345	.
O	1345	1348	15e
O	1348	1349	-
O	1349	1350	4
O	1350	1351	)
O	1351	1352	.

O	1353	1355	FN
O	1356	1358	in
O	1359	1367	patients
O	1368	1377	receiving
O	1378	1387	docetaxel
O	1388	1390	in
O	1391	1394	the
O	1395	1399	RAPP
O	1399	1400	-
O	1400	1402	01
O	1403	1408	trial
O	1409	1411	is
O	1412	1425	significantly
O	1426	1436	associated
O	1437	1441	with
O	1442	1445	the
O	1446	1455	haplotype
O	1456	1457	T
O	1457	1458	-
O	1458	1459	T
O	1460	1462	in
O	1463	1472	rs4762699
O	1473	1476	and
O	1477	1486	rs2857468
O	1487	1489	in
O	1490	1493	the
O	1494	1501	SLCO1A2
O	1502	1513	transporter
O	1514	1518	gene
O	1518	1519	.

O	1520	1524	This
O	1525	1531	result
O	1532	1538	should
O	1539	1541	be
O	1542	1551	validated
O	1552	1554	in
O	1555	1557	an
O	1558	1569	independent
O	1570	1576	cohort
O	1576	1577	.
